Price (delayed)
$5.27
Market cap
$255.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$255.13M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
There are no recent dividends present for ABEO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.